ArticleFrontiers in pharmacology2025
DX243 counteracts both acoustic trauma-induced reduction in cortical brain oscillations and cochlear synaptopathy.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes followingFrontiers in stroke · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With age, even mild acoustic injuries can accumulate - ultimately leading to a characteristic clinical picture of age-related hearing loss with the risk of cognitive decline. Age-related hearing loss is currently attributed to the loss of a most vulnerable auditory fiber type contributing to hearing in background noise. Here, we investigated the potential of a new drug, a more stable chemical variant of Dendrogenin B (DX243) that is predicted to display a protective function on neurite outgrowth, rather than on cell survival. Methodology: In the rat animal model, DX243 was tested on hearing thresholds, cortical local field potentials (LFP), auditory steady-state responses (ASSR), auditory brainstem responses (ABR), growth function of notched-noise stimuli, inner hair cell (IHC) ribbon numbers, and multi-click pulse responses (MCP) before and after auditory trauma (AT). Results: No auditory evoked LFP response changes were seen in the prefrontal cortex, visual cortex, or hippocampus. In contrast, a permanent decline of auditory evoked LFP amplitudes in the auditory cortex (AC) was measured 2 weeks after AT. Daily injection of DX243 for 2 weeks prevented the AT-induced decline in LFP activity, a protective effect that continued for 6 weeks following the final injection. Through a protective effect of DX243 on a trauma-induced decline of LFP in response to amplitude-modulated tones >80 Hz, a subcortical origin of the drug-effect was suggested. DX243 showed no effect on hearing sensitivity and did not affect subcortical processing of sound features that depend on phase-locking at the stimulus onset (e.g., near-threshold ASSR responses, close-to-threshold ABR growth functions, or spontaneous cortical LFP responses). However, with the same dose-response dependency as shown for cortical LFP effects, DX243 significantly protected from AT-induced decreases in ABR growth functions for loud sound stimuli and in background noise, protected from AT-induced loss of IHC ribbons and AT-induced decline of fast ABRs with decreasing time intervals. Conclusion: These findings suggest DX243 as a novel neuroprotective drug, that specifically protects auditory fibers contributing to the coding of the temporal envelope and detection of tones in masking noise, tasks of our auditory senses, both of which, if they fail, lead to age-related speech-in-noise comprehension deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.